Anti-HBV Activities of Xanthones From Swertia Punicea Hemsl

Xiu-Qiao Zhang, PhD, Jia-Chun Chen, PhD, Feng-Jiao Huang, MS, Luan-Yuan Tian, PhD, Yuan Tu, MS

Abstract


We studied the effects of two xanthones compounds isolated from Swertia punicea Hemsl (from Geutianaceae), swertianolin (I) and bellidifolin (II), on Hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) in cultured human hepatocellular carcinoma cell line (HepG2). The HepG2 cells were first cultured for 24h, various concentrations of these two xanthones were then added to the culture medium. The culture medium containing the two xanthones was exchanged once every 4 days. After 8 days, the cytotoxic activities of these two xanthones were assessed by cytopathic effect. The HepG2 cells were then treated with the two compounds at a concentration of swertianolin (1.6, 3.1, 6.2, 12.5, 25mg/ml) and bellidifolin (2.0, 3.9, 7.8, 25.5, 31.2mg/ml). Four or eight days later, the culture medium was collected and the expression of HBsAg and HBeAg were determined by radioimmunoassay. Our results show that swertianolin can suppress the expression of HBeAg with IC50 of 8.0mg/ml, while bellidifolin can inhibit the expression of HBsAg with IC50 of 13mg/ml at the eighth days. The Therapeutic Index for swertianolin and bellidifolin are 6.2 and 6.8, respectively. Our findings suggest that swertianolin and bellidifolin have anti-HBV activities in vitro.


Keywords


Swertia punicea Hemsl, swertianolin, bellidifolin, HepG2, HBsAg, HBeAg

Full Text:

PDF

References


Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373(9663):582-592.

Huang LM, Lu CY, Chen DS. Hepatitis B virus infection, its sequelae, and prevention by vaccination. Curr Opin Immunol. 2011;23(2):237-243.

Papatheodoridis GV, Manolakopou-los S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8(3):167-178.

Galan MV, Boyce D, Gordon SC. Current pharmacotherapy for hepatitis B infection. Expert Opin Phamiacother. 2001;2(8):1289-1298.

Tan P, Liu YL, Hou CY. The structure of swertiapuniside from Swertia punicea Hemsl. Yao Xue Xue Bao. 1992;27(6):476-479.

Tan P, Liu YL, Hou CY. The structure of swertiapunimarin from Swertia punicea Hemsl. Yao Xue Xue Bao. 1993;28(7):522-525.

Liu GM, Yang YS, Dong GP. Isolation and identification of oleanolic acid and mangiferin from Swertia punicea Hemsl. J. of DaLi Medical College. 1998; 7(1):7-9.

Qian JF, Liu GM, Huo M. Isolation and Identification of Xinthones from Swertia punicea Hemsl. J DaLi Medical College. 1998;7(4):5-7.

Cai DY, Zhao G, Chen JC, et al. Therapeutic effect of Zijing capsule in liver fibrositis rats. World J Gastroenterol. 1998;4(3):260-263.

Pang R, Tao J, Zhang S, et al. In vitro Anti-Hepatitis B Virus Effect of Hypericum perforatum L. Journal of Huazhong University of Science and Technology (Medical Science). 2010;30(1):98-102.

Wang WN, Yang XB, Liu HZ, Huang ZM, Wu GX. Effect of Oenanthe javanica flavone on human and duck hepatitis B virus infection. Acta Pharmacologica Sinica. 2005;26(5):587-592.

Lennette EH, Schmidt N. Diagnostic Procedures for Viral and Rickettsial Infections. 5nd ed. New York, American Public Health Association, Publishers; 1979.

Wan LS, Min QX, Wang YL, Yue YD, Chen JC. Xanthone glycoside constituents of Swertia kouitchensis with α-glucosidase inhibitory activity. J Nat Prod. 2013;76(7):1248-1253.

Tan GS, Xu PS, Tian HY, Xu KP, Dai ZY. Studies on the chemical constituents of Swertia davidii. Chinese Pharmaceutical Journal. 2000;35(7):441-443.

Zhang XQ, Tian LY, Chen JC, Liu YW. Constituents from Swertia Punicea Hemsl. Chin. Tradit. Herb Drugs. 2007;38(8):1153-1154.


Refbacks

  • There are currently no refbacks.